November 21, 2019

November 21, 2019

Subscribe to Latest Legal News and Analysis

November 20, 2019

Subscribe to Latest Legal News and Analysis

November 19, 2019

Subscribe to Latest Legal News and Analysis

Collateral Estoppel Does Not Attach To PTAB Invalidity Determination Pending Appeal

Recently, in Sanofi-Aventis v. Mylan, 2:17-cv-09105-SRC-CLW, Judge Stanley Chesler of the United States District Court, District of New Jersey, denied a motion by defendant Mylan for summary judgment of invalidity of asserted patent claims that were found to be obvious by the Patent Trial and Appeal Board (“PTAB”).  With the appeal of those decisions pending, Judge Chesler reasoned that the difference in the burdens of proof applicable at the PTAB and in instant case barred the application of issue preclusion under Supreme Court guidance in B&B Hardware, Inc. v. Hargis Indus., 135 S. Ct. 1293, 1303 (2015).

The case arose on October 24, 2017, when Sanofi-Aventis U.S. LLC, Sanofi-Aventis Deutschland GmbH, and Sanofi Winthrop Industrie (collectively, “Sanofi”), filed suit for patent infringement against Mylan N.V., Mylan GmbH, Mylan Inc., and Mylan Pharmaceuticals Inc. (collectively, “Mylan”), after Mylan filed a New Drug Application with the United States Food and Drug Administration (“FDA”) seeking approval to sell its proposed copies of Sanofi’s Lantus® and Lantus® SoloSTAR® drug products prior to the expiration of eighteen patents, including U.S. Patent Nos. 7,476,652 (“the ’652 patent”) and 7,713,930 (“the ’930 patent”) (together, the “formulation patents”).  The formulation patents relate to pharmaceutical formulation of acidic insulin having improved stability.

Prior to the filing of Sanofi’s complaint, Mylan had already petitioned for inter partes review (“IPR”) of the formulation patents in IPR2017-01526 (the ’652 patent) and IPR2017-01528 (the ’930 patent).  On December 13, 2017, the PTAB granted the petition and inter partes reviews were instituted for both patents.  One year later, in Final Written Decisions, the PTAB found all challenged claims of Sanofi’s formulation patents unpatentable as obvious.

Based on the rulings of the PTAB, Mylan moved for summary judgment of invalidity of the formulation patents, arguing that collateral estoppel barred Sanofi from relitigating that issue.  Sanofi countered by arguing that collateral estoppel cannot apply in instances where the first and second proceedings have differing standards of proof.  Based on B&B Hardware, which states that “issues are not identical if the second action involves application of a different legal standard, even though the factual setting of both suits may be the same,” the District Court held that differences in the legal standard, unlike procedural differences, do bar issue preclusion, before denying Mylan’s motion for summary judgment.  Specifically, the Court observed that patent owners in district court enjoy a presumption of patent validity that does not apply in post-grant proceedings where the burden to demonstrate obviousness is by a preponderance of the evidence, rather than by clear and convincing evidence.  The ruling by Judge Chesler also highlights the differences in legal effect for final PTAB decisions pending appeal at the Federal Circuit.  While Sanofi lived to fight another day, had Mylan been the unsuccessful party before the Board, it would have been statutorily estopped from renewing its obviousness arguments and any other invalidity position that it “raised or reasonably could have raised during that inter partes review” pursuant to 35 U.S.C. § 315(e)(2).

©1994-2019 Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. All Rights Reserved.

TRENDING LEGAL ANALYSIS


About this Author

Adam Samansky, Mintz Levin Law Firm, Boston, Patent Litigation Attorney
Member

Adam’s practice focuses on intellectual property litigation. He handles patent, trademark, and trade secret matters on behalf of innovators and investors in a range of industries. His core practice includes patent and trade secret litigation involving complex technologies in the pharmaceutical, medical, high-tech, and defense industries. Adam has tried cases before multiple US District Courts, briefed and argued cases before the US Court of Appeals for the Federal Circuit, and has briefed bet-the-company issues before the US Supreme Court.

617-348-1819
Peter J. Cuomo, Mintz Levin, Patent Litigation Lawyer, Expert Discovery Attorney,Patent Litigation IPRs & Other Post-Grant Proceedings Federal Circuit Appeals Hatch-Waxman ,ANDA Litigation Federal District Court
Of Counsel

Peter’s practice involves intellectual property enforcement and defense, and client counseling on issues related to IP rights. Peter's primary focus is in patent litigation where he has experience in every phase from pre-suit investigations through appeal, including, initial evaluation and case initiation, fact and expert discovery, pre-and post-trial motion practice, and trials and appeals. In addition to suits centered on the assertion and defense of infringement claims, Peter has experience with the successful resolution of multiple inventorship disputes and related misappropriation claims.

Peter has represented clients across a wide range of technologies such as biotechnology inventions, automotive parts, medical and mechanical devices, consumer products. He has also worked on numerous high-stakes Hatch-Waxman litigations for major pharmaceutical companies through trial and appeals. In addition to patent litigation, Peter has experience in disputes involving breach of contracts, unfair competition, trademarks and trade secret misappropriation claims.

Peter is a registered patent attorney licensed to practice and argue before the United States Patent and Trademark Office. In addition to representing clients in US District Courts and the US Court of Appeals for the Federal Circuit, he has experience in multiple post-grant proceedings before the Patent Trial and Appeal Board and its predecessor. He also provides patent and product analyses, and evaluations of prior art related to infringement and invalidity opinions.

Prior to joining the firm, he practiced in the intellectual property litigation practice in the Boston office of another international law firm. Peter also previously worked in and supervised an academic laboratory focused on researching infectious diseases. He is a co-author on multiple scientific papers and spent time in Zambia investigating the co-infection of measles and HIV. During law school, Peter was an editor on the Boston University Journal of Science and Technology Law and worked as a research assistant in intellectual property and the Health Law Department.

617-348-1854
Nana Liu Associate Mintz Life Sciences, Pharmaceuticals,Patent Litigation, International Trade Commission, Hatch-Waxman,  ANDA Litigation,
Associate

Nana focuses her practice on intellectual property litigation, including matters at the International Trade Commission (ITC) and Hatch-Waxman pharmaceutical cases. She also assists with litigation in federal district courts and appellate litigation at the US Court of Appeals for the Federal Circuit. She primarily represents companies in the life sciences industry.

Prior to joining Mintz Levin, Nana served as a judicial law clerk to the now-retired Hon. Andrew R. Grainger of the Massachusetts Appeals Court.

While earning her law degree, Nana was a law clerk at a Massachusetts-...

617-348-1703